molecular-glue-discovery-agent

<!--

COPYRIGHT NOTICE

This file is part of the "Universal Biomedical Skills" project.

Copyright (c) 2026 MD BABU MIA, PhD <md.babu.mia@mssm.edu>

All Rights Reserved.

#

This code is proprietary and confidential.

Unauthorized copying of this file, via any medium is strictly prohibited.

#

Provenance: Authenticated by MD BABU MIA

-->

---

name: 'molecular-glue-discovery-agent'

description: 'AI-powered molecular glue discovery for targeted protein degradation, enabling neo-substrate recruitment and undruggable target degradation through E3 ligase interface modulation.'

measurable_outcome: Execute skill workflow successfully with valid output within 15 minutes.

allowed-tools:

• read_file
• run_shell_command

---

Molecular Glue Discovery Agent

The Molecular Glue Discovery Agent enables AI-driven discovery of molecular glue degraders that induce protein-protein interactions between E3 ligases and neo-substrates for targeted protein degradation. Unlike PROTACs, molecular glues are smaller, more drug-like molecules that can access previously "undruggable" targets through induced proximity mechanisms.

When to Use This Skill

• When discovering new molecular glue scaffolds.
• For identifying neo-substrate targets for existing glues.
• To design glues for specific E3-substrate pairs.
• When optimizing glue selectivity and potency.
• For virtual screening of glue candidates.

Core Capabilities

1. Glue Scaffold Discovery: Identify novel molecular glue chemotypes.

1. Neo-Substrate Prediction: Predict proteins degraded by glues.

1. Interface Modeling: Model E3-glue-substrate ternary interfaces.

1. Selectivity Optimization: Design for specific substrate profiles.

1. SAR Analysis: Structure-activity relationship modeling.

1. Virtual Screening: Screen compounds for glue activity.

Molecular Glue Mechanisms

| Class | E3 Ligase | Mechanism | Example |

|-------|-----------|-----------|---------|

| IMiDs | CRBN | Degron recognition | Lenalidomide |

| CELMoDs | CRBN | Enhanced IKZF binding | Iberdomide |

| DCAF15 Glues | DCAF15 | Splicing factor degradation | Indisulam |

| CDK12 Glues | DDB1-CRBN | Cyclin K degradation | CR8 derivatives |

| β-catenin Glues | Novel | WNT pathway targets | Emerging |

Key Neo-Substrates

| Substrate | Glue Class | Disease Relevance |

|-----------|------------|-------------------|

| IKZF1/3 | IMiDs | Multiple myeloma |

| CK1α | Lenalidomide | MDS del(5q) |

| GSPT1 | CC-885 | AML |

| RBM39 | Indisulam | Solid tumors |

| Cyclin K | CR8 | Cancer |

| SALL4 | Thalidomide | Teratogenicity |

Workflow

1. Input: Target substrate, E3 ligase, screening library.

1. Interface Analysis: Model E3 surface and potential binding sites.

1. Virtual Screening: Screen compounds for interface binding.

1. Glue Scoring: Predict neo-substrate recruitment potential.

1. Selectivity Analysis: Predict off-target degradation.

1. Optimization: Iterative design for potency/selectivity.

1. Output: Ranked glue candidates with predicted profiles.

Example Usage

User: "Discover molecular glues that degrade IKZF1 through CRBN with improved selectivity over IKZF3."

Agent Action:

python3 Skills/Drug_Discovery/Molecular_Glue_Discovery_Agent/discover_glue.py \
    --target_substrate IKZF1 \
    --e3_ligase CRBN \
    --selectivity_against IKZF3 \
    --scaffold_library imid_derivatives.sdf \
    --interface_model crbn_ikzf1_complex.pdb \
    --n_candidates 100 \
    --output glue_discovery/

Glue Design Parameters

| Parameter | Consideration | Optimization |

|-----------|---------------|--------------|

| Interface Complementarity | E3-substrate fit | Shape/electrostatics |

| Degron Recognition | Substrate degron motifs | Motif compatibility |

| Binding Cooperativity | Positive cooperativity | Enhanced ternary |

| Selectivity | Off-target degradation | Substrate specificity |

| Drug Properties | MW, solubility, permeability | Standard optimization |

Output Components

| Output | Description | Format |

|--------|-------------|--------|

| Glue Candidates | Ranked molecules | .sdf, SMILES |

| Predicted Substrates | Neo-substrate profiles | .csv |

| Interface Models | Ternary complex structures | .pdb |

| Selectivity Scores | On-target vs off-target | .csv |

| Degradation Predictions | DC50, Dmax estimates | .csv |

| SAR Analysis | Structure-activity trends | .json |

AI/ML Components

Interface Prediction:

• Protein-protein docking
• Molecular surface analysis
• Deep learning interface scoring

Neo-Substrate Discovery:

• Degron motif prediction
• Proteome-wide screening
• Structural similarity to known substrates

Glue Optimization:

• Generative chemistry
• Multi-objective optimization
• Active learning for synthesis prioritization

Glue vs PROTAC Comparison

| Feature | Molecular Glue | PROTAC |

|---------|----------------|--------|

| Molecular Weight | <500 Da | 700-1500 Da |

| Target Discovery | Serendipitous/AI | Rational |

| Selectivity | Can be exquisite | Often broader |

| Substrate Range | Induced neo-substrates | Direct binders |

| Oral Bioavailability | Generally better | Challenging |

Clinical Pipeline (2026)

| Drug | Mechanism | Target | Phase |

|------|-----------|--------|-------|

| Iberdomide (CC-220) | CELMoD | IKZF1/3, Aiolos | Phase 3 |

| Mezigdomide (CC-92480) | CELMoD | IKZF1/3 | Phase 3 |

| Golcadomide (CC-99282) | CELMoD | IKZF1/3 | Phase 2 |

| CFT7455 | IKZF1/3 | IKZF1/3 | Phase 1 |

Degron Motif Analysis

| Degron Type | Sequence Features | E3 Recognition |

|-------------|-------------------|----------------|

| Zinc Finger | C2H2 ZF domain | CRBN-IMiD |

| Phosphodegron | pSer/pThr motifs | SCF E3s |

| N-degron | N-terminal residues | UBR1/2 |

| Hydrophobic | Exposed hydrophobics | Quality control |

Prerequisites

• Python 3.10+
• RDKit, Molecular modeling tools
• AlphaFold2/3, docking software
• Deep learning frameworks
• Protein structure databases

Related Skills

• PROTAC_Design_Agent - Bifunctional degraders
• TPD_Ternary_Complex_Agent - Complex modeling
• Virtual_Screening_Agent - High-throughput screening
• Protein_Protein_Docking_Agent - PPI modeling

Discovery Strategies

| Strategy | Approach | Success Examples |

|----------|----------|------------------|

| Phenotypic Screening | Degradation readout | IMiDs, indisulam |

| Target-Based | E3-substrate docking | Rational glues |

| Chemoproteomics | Pull-down identification | Neo-substrate discovery |

| AI-Guided | Computational prediction | Emerging |

Special Considerations

1. Polypharmacology: Glues often degrade multiple substrates
2. Species Differences: Neo-substrates may differ across species
3. Resistance: Substrate mutations, E3 downregulation
4. Toxicity: Off-target degradation (e.g., SALL4)
5. Hook Effect: Less common than PROTACs

Quality Control

| Metric | Purpose | Threshold |

|--------|---------|-----------|

| Interface Score | Complex stability | >0.6 |

| Cooperativity | Enhanced binding | >1.5 |

| Selectivity Index | On/off-target ratio | >10 |

| Drug-likeness | Developability | Lipinski compliant |

Future Directions

| Direction | Status | Potential |

|-----------|--------|-----------|

| New E3 Ligases | Active research | Expanded target space |

| Protein-Protein Glues | Emerging | Beyond degradation |

| AI-First Discovery | Advancing | Reduced serendipity |

| Combination Glues | Conceptual | Multi-target degradation |

Author

AI Group - Biomedical AI Platform

<!-- AUTHOR_SIGNATURE: 9a7f3c2e-MD-BABU-MIA-2026-MSSM-SECURE -->